RxDoctor Payments Data

Xylona Bibal, MD

Internal Medicine · San Francisco, CANPI 1699112169

Payments from drug & device makers

$1,779in general payments, 2019–2025

Across 95 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$807
  • AbbVie$192
  • Novo Nordisk$103
  • Gilead$89
  • GSK$79
  • Boehringer Ingelheim$79
  • plus $430 from 12 others

What the payments were for

  • Food & beverage$1,72797%
  • Education$523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,779 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$21,155
Medicare patients
86
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$25,165
JardianceEmpagliflozin11$18,305
OzempicSemaglutide14$15,793
FarxigaDapagliflozin Propanediol12$14,251
XareltoRivaroxaban15$12,561
Breo ElliptaFluticasone/Vilanterol12$7,546
Spiriva HandihalerTiotropium Bromide12$6,037
Atorvastatin Calcium342$3,151
Levothyroxine Sodium142$1,795
Losartan Potassium132$1,530
Olmesartan Medoxomil60$1,380
Amlodipine Besylate176$1,070
Rosuvastatin Calcium52$967
Ezetimibe40$914
Lisinopril97$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$25,16515 claims
Boehringer IngelheimJardiance$79$18,30511 claims
Novo NordiskOzempic$103$15,79314 claims
AstraZenecaFarxiga$37$14,25112 claims
Johnson & JohnsonXarelto$41$12,56115 claims
GSKBreo Ellipta$79$7,54612 claims
AbbVieSynthroid$192$25615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →